Dorota Borys
About
Dorota Borys is a scholar working on Epidemiology, Microbiology and Pediatrics, Perinatology and Child Health.
According to data from OpenAlex, Dorota Borys has authored 71 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Epidemiology, 54 papers in Microbiology and 4 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Dorota Borys's work include Pneumonia and Respiratory Infections (65 papers), Bacterial Infections and Vaccines (52 papers) and Respiratory viral infections research (36 papers). Dorota Borys is often cited by papers focused on Pneumonia and Respiratory Infections (65 papers), Bacterial Infections and Vaccines (52 papers) and Respiratory viral infections research (36 papers). Dorota Borys collaborates with scholars based in Belgium, United States and United Kingdom. Dorota Borys's co-authors include Lode Schuerman, Patricia Lommel, Roman Prymula, Magali Traskine, Marta Moreira, Taneli Puumalainen, Nancy François, Arto A. Palmu, Heta Nieminen and Terhi Kilpi and has published in prestigious journals such as The Lancet, PLoS ONE and PEDIATRICS.
In The Last Decade
Dorota Borys
69 papers receiving 1.7k citations
Peers
Dorota Borys
Patricia Lommel Belgium
Ángela Gentile Argentina
Rimma Melamed Israel
Mark McMillan Australia
Juan José García‐García Spain
Taina Juvén Finland
Andrew Riordan United Kingdom
Tarja Heiskanen‐Kosma Finland
Elina Lahti Finland
K.A. Deaver United States
Citations per year, relative to Dorota Borys Dorota Borys (= 1×)
peers
Patricia Lommel
Countries citing papers authored by Dorota Borys
Since
Specialization
Citations
This map shows the geographic impact of Dorota Borys's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dorota Borys with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dorota Borys more than expected).
Fields of papers citing papers by Dorota Borys
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Dorota Borys. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dorota Borys. The network helps show where Dorota Borys may publish in the future.
Co-authorship network of co-authors of Dorota Borys
This figure shows the co-authorship network connecting the top 25 collaborators of Dorota Borys. A scholar is included among the top collaborators of Dorota Borys based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dorota Borys. Dorota Borys is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Borys, Dorota, Ronald Smulders, Miwa Haranaka, et al.. (2024). Safety, reactogenicity, and immunogenicity of a novel 24-valent pneumococcal vaccine candidate in healthy, pneumococcal vaccine-naïve Japanese adults: A phase 1 randomized dose-escalation trial. Vaccine. 44. 126545–126545.
2.
Borys, Dorota, Richard Rupp, Ronald Smulders, et al.. (2024). Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: A phase 1 randomized controlled trial. Vaccine. 42(10). 2560–2571.
3.
Nunes, Marta C., Marta Moreira, Anthonet Koen, et al.. (2020). Bacterial nasopharyngeal carriage following infant immunization with pneumococcal conjugate vaccines according to a 2+1 schedule in children in South Africa: an exploratory analysis of two clinical trials. Expert Review of Vaccines. 19(12). 1177–1189.
4.
Madhi, Shabir A., Marta Moreira, Anthonet Koen, et al.. (2020). Impact of HIV status and vaccination schedule on bacterial nasopharyngeal carriage following infant immunisation with the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in South Africa. Vaccine. 38(10). 2350–2360.
5.
Sáfadi, Marco Aurélio Palazzi, Federico Martinón‐Torres, Lily Yin Weckx, et al.. (2019). Immunogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) administered concomitantly with the meningococcal serogroup B (4CMenB) vaccine in infants: A post-hoc analysis in a phase 3b, randomised, controlled trial. Vaccine. 37(35). 4858–4863.
6.
Nieminen, Heta, Hanna Rinta‐Kokko, Janne J. Jokinen, et al.. (2019). Effectiveness of the 10-valent pneumococcal conjugate vaccine among girls, boys, preterm and low-birth-weight infants – Results from a randomized, double-blind vaccine trial. Vaccine. 37(28). 3715–3721.
7.
Mrkvan, Tomáš, Stephen I. Pelton, Javier Ruiz‐Guiñazú, Arto A. Palmu, & Dorota Borys. (2018). Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience. Expert Review of Vaccines. 17(9). 797–818.
8.
Zaman, Khalequ, Asma Binte Aziz, Magali Traskine, et al.. (2017). Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized study. Vaccine. 36(5). 698–706.
9.
Madhi, Shabir A., Anthonet Koen, Lisa Jose, et al.. (2017). Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status. Medicine. 96(2). e5881–e5881.
10.
Vesikari, Timo, Aino Forstén, Tarja Kaijalainen, et al.. (2016). Effectiveness of the 10-Valent Pneumococcal NontypeableHaemophilus influenzaeProtein D–Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media—A Double-Blind Randomized Clinical Trial in Finland. Journal of the Pediatric Infectious Diseases Society. 5(3). 237–248.
11.
Palmu, Arto A., Janne J. Jokinen, Heta Nieminen, et al.. (2014). Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial. STM:n Hallinnonalan avoin julkaisuarkisto (Julkari).
12.
Leroux‐Roels, Geert, Cathy Maes, Fien De Boever, et al.. (2014). Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: A phase I/II randomized clinical study. Vaccine. 32(50). 6838–6846.
13.
Borys, Dorota, et al.. (2012). Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa-HBV-IPV/Hib in Vietnamese infants. International Journal of Infectious Diseases. 16. e304–e304.
14.
Ruiz‐Palacios, Guillermo M., Li‐Min Huang, Tzou‐Yien Lin, et al.. (2012). Immunogenicity and Safety of a Booster Dose of the 10-valent Pneumococcal Haemophilus Influenzae Protein D Conjugate Vaccine Coadministered With the Tetravalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine in Toddlers. The Pediatric Infectious Disease Journal. 32(1). 62–71.
15.
Kim, Chang Hwi, Jung Soo Kim, Sung Ho, et al.. (2011). Response to Primary and Booster Vaccination With 10-valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine in Korean Infants. The Pediatric Infectious Disease Journal. 30(12). e235–e243.
16.
Silfverdal, Sven‐Arne, et al.. (2011). Anamnestic Immune Response in 3- to 4-year-old Children Previously Immunized With 10-valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine as 2-dose or 3-dose Priming and a Booster Dose in the First Year of Life. The Pediatric Infectious Disease Journal. 30(9). e155–e163.
17.
Silfverdal, Sven‐Arne, et al.. (2009). Immunogenicity of a 2-Dose Priming and Booster Vaccination With the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine. The Pediatric Infectious Disease Journal. 28(10). e276–e282.
18.
Schuerman, Lode, Dorota Borys, Bernard Hoet, Arne Forsgren, & Roman Prymula. (2009). Prevention of otitis media: Now a reality?. Vaccine. 27(42). 5748–5754.
19.
Prymula, Roman, Claire‐Anne Siegrist, Roman Chlíbek, et al.. (2009). Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. The Lancet. 374(9698). 1339–1350.
20.
Chevallier, Bertrand, Timo Vesikari, Jerzy Brzostek, et al.. (2009). Safety and Reactogenicity of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) When Coadministered With Routine Childhood Vaccines. The Pediatric Infectious Disease Journal. 28(4). S109–S118.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Patricia Lommel Breakdown of academic impact, for papers by Ángela Gentile Breakdown of academic impact, for papers by Rimma Melamed Breakdown of academic impact, for papers by Mark McMillan Breakdown of academic impact, for papers by Juan José García‐García Breakdown of academic impact, for papers by Taina Juvén Breakdown of academic impact, for papers by Andrew Riordan Breakdown of academic impact, for papers by Tarja Heiskanen‐Kosma Breakdown of academic impact, for papers by Elina Lahti Breakdown of academic impact, for papers by K.A. Deaver